Iohexol ( DrugBank: Iohexol )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
19ライソゾーム病2
67多発性嚢胞腎1

19. ライソゾーム病


臨床試験数 : 899 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01839526
(ClinicalTrials.gov)
May 201311/4/2013A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry DiseaseA Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry DiseaseFabry DiseaseDrug: IohexolGenzyme, a Sanofi CompanyNULLTerminated5 Years25 YearsMale39N/AUnited States;Argentina;Austria;Belgium;Brazil;Canada;Finland;France;Hungary;Norway;Poland;Spain;Taiwan;United Kingdom
2EUCTR2012-001966-14-ES
(EUCTR)
25/10/201203/09/2012A study to assess the renal function in young male patients with Fabry disease who have never received any specific treatment for this disease.A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients with Fabry Disease - FABRY-MAP Fabry disease
MedDRA version: 15.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Iohexol
Product Name: OMNIPAQUE
Product Code: Not applicable
INN or Proposed INN: iohexol
Other descriptive name: iohexol
Genzyme, a Sanofi CompanyNULLNot RecruitingFemale: no
Male: yes
45Phase 1United States;Canada;Spain;Norway;Netherlands;United Kingdom

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04407481
(ClinicalTrials.gov)
November 1, 202019/5/2020PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)PENGUIN: PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKDPolycystic Kidney Disease, Adult;Polycystic Kidney, Autosomal DominantDrug: Aminohippurate Sodium Inj 20%;Drug: Iohexol Inj 300 milligrams per milliliter (MG/ML);Radiation: PET/CT ScanUniversity of Colorado, DenverNULLCompleted18 Years40 YearsAll22United States